Mustang Bio Inc (MBIO) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Mustang Bio Inc (MBIO) has a cash flow conversion efficiency ratio of -0.084x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-818.00K) by net assets ($9.77 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Mustang Bio Inc - Cash Flow Conversion Efficiency Trend (2016–2024)
This chart illustrates how Mustang Bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read Mustang Bio Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Mustang Bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Mustang Bio Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
amalphi ag
F:AMI
|
N/A |
|
Vinvest Capital Holdings Bhd
KLSE:0069
|
-0.012x |
|
HB Stockholdings Limited
NSE:HBSL
|
-0.126x |
|
COPPERCORP RESOURCES INC.
F:NU0
|
N/A |
|
BetterLife Pharma Inc
F:NPAU
|
0.030x |
|
Elevai Labs, Inc. Common Stock
NASDAQ:ELAB
|
-0.223x |
|
HITIQ Ltd
AU:HIQ
|
0.464x |
|
Fidelity Asian Values
LSE:FAS
|
0.000x |
Annual Cash Flow Conversion Efficiency for Mustang Bio Inc (2016–2024)
The table below shows the annual cash flow conversion efficiency of Mustang Bio Inc from 2016 to 2024. For the full company profile with market capitalisation and key ratios, see Mustang Bio Inc (MBIO) market capitalisation.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-3.87 Million | $-11.41 Million | 2.946x | +100.73% |
| 2023-12-31 | $123.00K | $-49.48 Million | -402.252x | -28506.97% |
| 2022-12-31 | $46.27 Million | $-65.07 Million | -1.406x | -194.50% |
| 2021-12-31 | $112.40 Million | $-53.67 Million | -0.477x | -25.94% |
| 2020-12-31 | $98.44 Million | $-37.32 Million | -0.379x | +41.69% |
| 2019-12-31 | $51.65 Million | $-33.58 Million | -0.650x | -22.96% |
| 2018-12-31 | $36.40 Million | $-19.24 Million | -0.529x | -144.33% |
| 2017-12-31 | $59.83 Million | $-12.95 Million | -0.216x | -27.23% |
| 2016-12-31 | $24.28 Million | $-4.13 Million | -0.170x | -- |
About Mustang Bio Inc
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating cell therapies into cures for difficult-to-treat cancers and autoimmune diseases. It develops MB-106, a CD20-targeted chimeric antigen receptor (CAR) T cell therapy for non-hodgkin lymphoma, chronic lymphocytic leukemia, and autoimmune diseases; MB-101, an IL13Ra2 CAR T cell program for glioblastoma; and MB-108 … Read more